CN116250570A - Infant formula milk powder and preparation method thereof - Google Patents
Infant formula milk powder and preparation method thereof Download PDFInfo
- Publication number
- CN116250570A CN116250570A CN202211474362.5A CN202211474362A CN116250570A CN 116250570 A CN116250570 A CN 116250570A CN 202211474362 A CN202211474362 A CN 202211474362A CN 116250570 A CN116250570 A CN 116250570A
- Authority
- CN
- China
- Prior art keywords
- infant formula
- content
- protein
- powder
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 263
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 206
- 235000013336 milk Nutrition 0.000 title claims abstract description 107
- 210000004080 milk Anatomy 0.000 title claims abstract description 107
- 239000008267 milk Substances 0.000 title claims abstract description 107
- 238000002360 preparation method Methods 0.000 title abstract description 34
- 235000018102 proteins Nutrition 0.000 claims abstract description 200
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 200
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 200
- 102000011632 Caseins Human genes 0.000 claims abstract description 167
- 108010076119 Caseins Proteins 0.000 claims abstract description 167
- 239000000203 mixture Substances 0.000 claims abstract description 142
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 128
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 125
- 235000021119 whey protein Nutrition 0.000 claims abstract description 119
- 235000021247 β-casein Nutrition 0.000 claims abstract description 109
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 84
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 84
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 84
- 235000019621 digestibility Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims description 82
- 235000016709 nutrition Nutrition 0.000 claims description 69
- 230000035764 nutrition Effects 0.000 claims description 64
- 239000005018 casein Substances 0.000 claims description 51
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 49
- 235000021240 caseins Nutrition 0.000 claims description 49
- 235000015097 nutrients Nutrition 0.000 claims description 33
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 32
- 239000011707 mineral Substances 0.000 claims description 32
- 235000010755 mineral Nutrition 0.000 claims description 32
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 31
- 239000003925 fat Substances 0.000 claims description 30
- 235000019197 fats Nutrition 0.000 claims description 30
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 29
- 239000005862 Whey Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 27
- 235000020183 skimmed milk Nutrition 0.000 claims description 27
- 239000003921 oil Substances 0.000 claims description 26
- 235000019198 oils Nutrition 0.000 claims description 26
- 239000008101 lactose Substances 0.000 claims description 24
- 230000001954 sterilising effect Effects 0.000 claims description 23
- -1 compound vitamin Chemical class 0.000 claims description 22
- 241000186000 Bifidobacterium Species 0.000 claims description 21
- 229940088594 vitamin Drugs 0.000 claims description 21
- 229930003231 vitamin Natural products 0.000 claims description 21
- 235000013343 vitamin Nutrition 0.000 claims description 21
- 239000011782 vitamin Substances 0.000 claims description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 229960004488 linolenic acid Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims description 15
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 14
- 235000020778 linoleic acid Nutrition 0.000 claims description 14
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- 239000003549 soybean oil Substances 0.000 claims description 13
- 235000012424 soybean oil Nutrition 0.000 claims description 13
- 235000005687 corn oil Nutrition 0.000 claims description 12
- 239000002285 corn oil Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 10
- 235000019743 Choline chloride Nutrition 0.000 claims description 10
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 10
- 229960003178 choline chloride Drugs 0.000 claims description 10
- 235000008939 whole milk Nutrition 0.000 claims description 10
- 108010063045 Lactoferrin Proteins 0.000 claims description 9
- 102000010445 Lactoferrin Human genes 0.000 claims description 9
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 9
- 235000021242 lactoferrin Nutrition 0.000 claims description 9
- 229940078795 lactoferrin Drugs 0.000 claims description 9
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 9
- 239000001103 potassium chloride Substances 0.000 claims description 9
- 235000011164 potassium chloride Nutrition 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 235000019486 Sunflower oil Nutrition 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- 239000002600 sunflower oil Substances 0.000 claims description 7
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 235000008476 powdered milk Nutrition 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000828 canola oil Substances 0.000 claims description 4
- 235000019519 canola oil Nutrition 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 235000013325 dietary fiber Nutrition 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 239000006041 probiotic Substances 0.000 claims description 4
- 235000018291 probiotics Nutrition 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 235000020238 sunflower seed Nutrition 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 235000021243 milk fat Nutrition 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- 229960001898 phytomenadione Drugs 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 229960005055 sodium ascorbate Drugs 0.000 claims description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 235000019624 protein content Nutrition 0.000 description 70
- 239000000523 sample Substances 0.000 description 58
- 230000029087 digestion Effects 0.000 description 53
- 230000000052 comparative effect Effects 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 230000002496 gastric effect Effects 0.000 description 25
- 102000007079 Peptide Fragments Human genes 0.000 description 23
- 108010033276 Peptide Fragments Proteins 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- 230000013777 protein digestion Effects 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 210000002784 stomach Anatomy 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 235000020776 essential amino acid Nutrition 0.000 description 12
- 239000003797 essential amino acid Substances 0.000 description 12
- 238000004806 packaging method and process Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 102000057297 Pepsin A Human genes 0.000 description 10
- 108090000284 Pepsin A Proteins 0.000 description 10
- 229940111202 pepsin Drugs 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000020185 raw untreated milk Nutrition 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000021249 α-casein Nutrition 0.000 description 8
- 235000020256 human milk Nutrition 0.000 description 7
- 210000004251 human milk Anatomy 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 4
- 102000008192 Lactoglobulins Human genes 0.000 description 4
- 108010060630 Lactoglobulins Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 4
- 235000020603 homogenised milk Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012764 semi-quantitative analysis Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007234 antiinflammatory process Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000020191 long-life milk Nutrition 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 241000372033 Andromeda Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001664542 Karima Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical group [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 238000002872 Statistical quality control Methods 0.000 description 1
- BLHYIYKUEYNCSP-UHFFFAOYSA-M [Na+].CC([O-])=O.C1CCOC1.CCN(CC)CC Chemical compound [Na+].CC([O-])=O.C1CCOC1.CCN(CC)CC BLHYIYKUEYNCSP-UHFFFAOYSA-M 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- AWBWZUHEUDDGKG-UHFFFAOYSA-M sodium acetonitrile methanol acetate Chemical compound [Na+].OC.CC#N.CC([O-])=O AWBWZUHEUDDGKG-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Dairy Products (AREA)
Abstract
The invention provides infant formula milk powder and a preparation method thereof. The infant formula contains a protein composition that enhances the digestibility of protein in the infant formula; wherein, based on 100 percent of the total protein content of the infant formula, the protein composition contains 13.0 to 50.5 percent of alpha-lactalbumin and 15.0 to 35.0 percent of beta-casein. By adopting the technical scheme of the invention, the digestibility of whey protein in infant formula milk powder can be obviously improved.
Description
Technical Field
The invention belongs to the technical field of infant formulas, and particularly relates to a formula milk powder and a preparation method thereof, in particular to a formula milk powder containing a protein composition for improving the protein digestion performance in foods and a preparation method thereof.
Background
Among the three most powerful nutrients, proteins are of great interest because of their important effects on mammalian pups, such as providing energy, promoting height, inhibiting bacteria and infection, promoting mineral absorption, etc.
The large differences in protein composition between milk and human milk indicate differences in physiological characteristics and growth patterns of different species, and the nutritional value of the milk is also different.
In general, proteins in foods are hydrolyzed to amino acids and short peptides, which are then absorbed, and since saliva does not contain enzymes that hydrolyze proteins, digestion of proteins begins in the stomach but mainly occurs in the small intestine. The enzyme for digesting protein in stomach is pepsin, which breaks down protein into peptone and small amount of polypeptide and amino acid, and the optimum pH value for pepsin to act is 1.8-3.5. Pepsin has a rennet effect on casein, and after forming milk mass, the pepsin stays in the stomach for a long time, so that digestion and absorption are facilitated, and the pepsin is very important for infants. Digestion of proteins in the small intestine is mainly accomplished by various proteases secreted by the pancreas (e.g., trypsin, etc.), which rapidly degrade proteins in the small intestine into amino acids and short peptides that can be taken up by small intestine epithelial cells.
It is thought that casein aggregates in the stomach, resulting in a long residence time in the stomach, and a prolonged gastric emptying time and protein digestion and absorption time. Under the combined action of the strong acid environment in the stomach and digestive enzymes, casein micelles are destroyed, and the casein micelles are combined with acid and pepsin to form a clot, so that the size of the clot can be reduced by increasing the proportion of beta-casein. However, since the spatial structure of the protein in the stomach is not easily destroyed, the prior studies report that the whey protein is not easily digested in the stomach, and can be thoroughly degraded into free amino acids only after entering the small intestine, and is used by the body after absorption. The spatial structure of alpha-lactalbumin (also known as alpha-lactalbumin) differs from that of beta-lactoglobulin, and in the case of gastric acid, an evacuated structure is more easily formed, so whether the digestibility can be improved by increasing the proportion of alpha-lactalbumin is a very serious problem.
Although proteins have the above-mentioned advantages and digestion properties, conventional infant formulas and the like have not yet improved digestion performance during infant digestion as compared to breast milk.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide the infant formula milk powder which can improve the protein digestion performance and is a protein composition, so that the protein in the infant formula milk powder is easier to digest and absorb and the effect of the infant formula milk powder is more similar to that of breast feeding.
In order to achieve the above object, the present invention provides an infant formula comprising a protein composition capable of improving the digestibility of proteins in the infant formula; wherein, based on 100 percent of the total protein content of the infant formula, the protein composition contains 13.0 to 50.5 percent of alpha-lactalbumin and 15.0 to 35.0 percent of beta-casein. The infant formula milk powder ensures that the protein has good digestion performance by controlling the composition and the content range of the protein in the infant formula milk powder, thereby promoting the digestion and absorption of the milk powder.
The protein composition capable of remarkably improving the digestibility of proteins (especially whey proteins) in infant formula is realized by controlling the content of alpha-whey proteins (the proportion of total proteins) and the content of beta-casein (the proportion of total proteins) in the infant formula.
According to a specific embodiment of the present invention, the improvement of the digestibility of proteins according to the present invention refers to an improvement of the digestibility of proteins of animal origin, such as proteins derived from animal milk, in particular proteins derived from cow milk.
According to a specific embodiment of the present invention, preferably, the improving protein digestion performance in infant formula comprises at least one of: increasing the digestibility of whey protein, increasing the type of free amino acids released, increasing the ratio of essential amino acids EAA released in the free amino acids released, increasing the production of small molecule peptides, increasing the type of characteristic peptide fragments produced, in particular increasing the ratio of essential amino acids EAA released in the free amino acids released.
According to the specific embodiment of the invention, the protein composition is a composition capable of improving the protein digestion performance in infant formula, and can be used for implementing the method for improving the protein digestion performance in infant formula provided by the invention, and the infant formula is obtained by combining the composition with other ingredients.
According to a specific embodiment of the present invention, preferably, the protein composition contains about 15.0% to 50.5% of alpha-lactalbumin, based on 100% total protein content of the infant formula.
According to a specific embodiment of the present invention, preferably the protein composition contains about 18.0% to 35.0% beta-casein, more preferably about 22.0% to 32.0%, even more preferably about 25.0% to 32.0% beta-casein, based on 100% total protein content of the infant formula.
According to a specific embodiment of the present invention, preferably, the protein composition contains about 20.0% to 35.0% of alpha-lactalbumin and about 26.0% to 32.0% of beta-casein, based on 100% total protein content of the infant formula.
According to a specific embodiment of the present invention, preferably, the protein composition contains about 21.0% to 32.0% of alpha-lactalbumin and about 29.0% to 32.0% of beta-casein, based on 100% total protein content of the infant formula. For example, the protein composition comprises about 32.0% alpha-lactalbumin and about 32.0% beta-casein, or alternatively the protein composition comprises about 29.0% alpha-lactalbumin and about 32.0% beta-casein, or alternatively the protein composition comprises about 21.5% alpha-lactalbumin and about 29.0% beta-casein, or alternatively the protein composition comprises about 21.0% alpha-lactalbumin and about 26.0% beta-casein, based on 100% total protein content of the infant formula.
According to a specific embodiment of the present invention, the whey protein content of the protein composition is preferably about 33.0% or more, for example 35.0% to 90.0%, preferably about 40.0% to 80.0%, more preferably about 50.0% to 75.0%, even more preferably about 60.0% to 70.0%, based on 100% total protein content of the infant formula.
According to a specific embodiment of the present invention, the casein content of the protein composition is preferably controlled to be about 15.0% or more, for example 15.0% -65.0%, preferably about 28.0% -60.0%, more preferably about 32.0% -55.0%, even more preferably about 38.0% -40.0% based on 100% of the total protein content of the infant formula.
The invention can control the content of whey protein and casein protein in the protein composition at the same time. Preferably, the whey protein content of the protein composition is controlled to about 40.0% -80.0% and the casein content is controlled to about 28.0% -60.0%, such as 60.0% and 40.0%, 50.0% and 50.0%, 70.0% and 30.0%.
According to a specific embodiment of the present invention, the protein composition is preferably added in an amount of 540 to 690 parts by weight based on 1000 parts by weight of the infant formula.
According to a specific embodiment of the present invention, the infant formula preferably has a total protein content of about 10.00-23.00g/100g, such as 10.00g/100g, 11.00g/100g, 12.00g/100g, 13.00g/100g, 14.00g/100g, 15.00g/100g, 16.00g/100g, 17.00g/100g, 18.00g/100g, 19.00g/100g, 20.00g/100g, 21.00g/100g, 22.00g/100g, 23.00g/100g, which may also be in the range of compositions ending with the specific content mentioned above, for example, 10.00-11.00g/100g, 10.00-12.00g/100g, 10.00-13.00g/100g, 10.00-14.00g/100g, 10.00-15.00g/100g, 10.00-16.00g/100g, 10.00-17.00g/100g, 10.00-18.00g/100g, 10.00-19.00g/100g, 10.00-20.00g/100g, 10.00-21.00g/100g, 10.00-22.00g/100g, 11.00-12.00g/100g, 11.00-13.00g/100g, 11.00-14.00g/100g, 11.00-15.00g/100g, 11.00-16.00g/100g, 11.00-17.00g/100g, 100g 11.00-18.00g/100g, 11.00-19.00g/100g, 11.00-20.00g/100g, 11.00-21.00g/100g, 11.00-22.00g/100g, 11.00-23.00g/100g, 12.00-13.00g/100g, 12.00-14.00g/100g, 12.00-15.00g/100g, 12.00-16.00g/100g, 12.00-17.00g/100g, 12.00-18.00g/100g, 12.00-19.00g/100g, 12.00-20.00g/100g, 12.00-21.00g/100g, 12.00-22.00g/100g, 12.00-23.00g/100g, 13.00-14.00g/100g, 12.00-22.00g/100g, 13.00-15.00g/100g, 13.00-16.00g/100g, 13.00-17.00g/100g, 13.00-18.00g/100g, 13.00-19.00g/100g, 13.00-20.00g/100g, 13.00-21.00g/100g, 13.00-22.00g/100g, 13.00-23.00g/100g, 14.00-15.00g/100g, 14.00-16.00g/100g, 14.00-17.00g/100g, 14.00-18.00g/100g, 14.00-19.00g/100g, 14.00-20.00g/100g, 14.00-21.00g/100g, 14.00-22.00g/100g, 14.00-23.00g/100g, 15.00-16.00g, 15.00-17.00g/100g, 14.00-18.00g/100g, 14.00-21.00g/100g, 14.00-22.00g, 15.00-23.00g/100g, 15.00-20.00g, 15.00g and 15.00-20.00g/100g 16.00-17.00g/100g, 16.00-18.00g/100g, 16.00-19.00g/100g, 16.00-20.00g/100g, 16.00-21.00g/100g, 16.00-22.00g/100g, 16.00-23.00g/100g, 17.00-18.00g/100g, 17.00-19.00g/100g, 17.00-20.00g/100g, 17.00-21.00g/100g, 17.00-22.00g/100g, 17.00-23.00g/100g 18.00-19.00g/100g, 18.00-20.00g/100g, 18.00-21.00g/100g, 18.00-22.00g/100g, 18.00-23.00g/100g, 19.00-20.00g/100g, 19.00-21.00g/100g, 19.00-22.00g/100g, 19.00-23.00g/100g, 20.00-21.00g/100g, 20.00-22.00g/100g, 21.00-23.00g/100g, 21.00-22.00g/100g, 21.00-23.00g/100g, 22.00-23.00g/100g, etc.
According to a specific embodiment of the present invention, the infant formula preferably has an alpha-lactalbumin content of about 1.50-5.30g/100g and a beta-casein content of about 2.00-5.20g/100g.
According to a specific embodiment of the invention, the infant formula may contain different amounts of α -lactalbumin, β -casein, wherein:
the content of alpha-lactalbumin may be 1.50g/100g, 2.00g/100g, 2.20g/100g, 2.40g/100g, 3.00g/100g, 3.30g/100g, 4.00g/100g, 4.60g/100g, 5.00g/100g, 5.30g/100g; the content of alpha-lactalbumin may also be in a range of combinations with the specific content indicated above as an endpoint, for example 1.50-2.00g/100g, 1.50-2.20g/100g, 1.50-2.40g/100g, 1.50-3.00g/100g, 1.50-3.30g/100g, 1.50-4.00g/100g, 1.50-4.60g/100g, 1.50-5.00g/100g, 1.50-5.30g/100g, 2.00-2.20g/100g, 2.00-2.40g/100g, 2.00-3.00g/100g, 2.00-3.30g/100g, 2.00-4.00g/100g, 2.00-4.60g/100g, 2.00-5.00g/100g, 2.00-5.30g/100g, 2.20-2.40g/100g, 2.20-3.00g, 2.00-3.00g/100g, 2.00-3.00g, 3.00g/100g, 2.60 g and 2.60 g/100g 2.20-4.60g/100g, 2.20-5.00g/100g, 2.20-5.30g/100g, 2.40-3.00g/100g, 2.40-3.30g/100g, 2.40-4.00g/100g, 2.40-4.60g/100g, 2.40-5.00g/100g, 2.40-5.30g/100g, 3.00-3.30g/100g, 3.00-4.00g/100g, 3.30-4.60g/100g, 3.30-5.00g/100g, 3.30-5.30g/100g, 4.00-4.60g/100g, 4.00-5.00g/100g, 4.00-5.30g/100g, 4.60-5.00g/100g, 4.60-5.30g/100g, 5.00-5.30g, 5.00-5.100 g, etc.;
The content of beta-casein may be 2.00g/100g, 2.50g/100g, 3.00g/100g, 3.50g/100g, 4.00g/100g, 4.50g/100g, 5.00g/100g, 5.20g/100g; beta-casein may also be in a range having the above specific amounts as end combinations, for example, 2.00-2.50g/100g, 2.00-3.00g/100g, 2.00-3.50g/100g, 2.00-4.00g/100g, 2.00-4.50g/100g, 2.00-5.00g/100g, 2.00-5.20g/100g, 2.50-3.00g/100g, 2.50-3.50g/100g, 2.50-4.00g/100g, 2.50-4.50g/100g, 2.50-5.00g/100g, 2.50-5.20g/100g, 3.00-3.50g/100g, 3.00-4.00g/100g, 3.00-4.50g/100g, 3.00-5.20g/100g, 3.50-4.00g/100g, 3.00-4.00g/100g, 3.50-4.00g/100g, 2.50-5.00g/100g, 2.00-5.00g/100g, 2.00-5.20g, 2.00-5.00g, 2.00-5.20g/100g, 2.00-5.00g, 3.00-5.00g, 2.00 g-100 g, 3.00-5.00g, 2.00g, 3.00-5.100 g, 3.00g, 2.100 g-5.100 g, 3.100 g-5.100 g and 100 g.
The above-mentioned alpha-lactalbumin, beta-casein content may be combined or in other specific combinations, for example: the content of alpha-lactalbumin is 2.38g/100g, and the content of beta-casein is 3.20g/100g; alternatively, the content of alpha-lactalbumin is 3.343g/100g and the content of beta-casein is 4.13g/100g; alternatively, the content of alpha-lactalbumin is 3.43g/100g and the content of beta-casein is 4.61g/100g; alternatively, the content of alpha-lactalbumin is 4.642g/100g and the content of beta-casein is 5.122g/100g; alternatively, the content of alpha-lactalbumin is 5.117g/100g and the content of beta-casein is 5.127g/100g; alternatively, the content of alpha-lactalbumin is 1.795g/100g and the content of beta-casein is 2.386g/100g; alternatively, the content of alpha-lactalbumin is 2.224g/100g and the content of beta-casein is 3.036g/100g; alternatively, the content of alpha-lactalbumin is 1.572g/100g and the content of beta-casein is 2.102g/100g; alternatively, the content of alpha-lactalbumin is 2.208g/100g, and the content of beta-casein is 3.027g/100g; alternatively, the content of alpha-lactalbumin is 3.355g/100g and the content of beta-casein is 3.363g/100g; alternatively, the content of alpha-lactalbumin is 1.585g/100g, and the content of beta-casein is 2.097g/100g; alternatively, the content of alpha-lactalbumin is 5.264g/100g, and the content of beta-casein is 2.108g/100g, etc.
According to a specific embodiment of the present invention, preferably, the protein composition is prepared from one or more raw materials including liquid milk (e.g., milk), milk powder, whey protein powder, casein powder, which may also be derived from whey powder, lactoferrin, hydrolyzed protein, etc.; the liquid milk comprises whole milk and/or skim milk; the starting material for the protein composition may further comprise lactose. Wherein the milk powder preferably comprises whole milk powder (or whole milk powder) and/or skimmed milk powder (or skimmed milk powder); the whey protein powder preferably comprises concentrated whey protein powder with different protein contents and whey protein powder with different alpha-whey protein contents; the casein powder preferably comprises casein powder of different beta-casein content. Wherein, the milk powder, the whey protein powder and the casein powder are used as protein sources, the addition amount of the milk powder, the whey protein powder and the casein powder is used as alpha-lactalbumin and beta-casein sources respectively, and the addition amount of the milk powder, the whey protein powder and the casein powder is used as protein sources, and the addition amount of the milk powder, the casein powder and the casein powder is used as the basis for meeting the content range requirement of the whey protein.
The protein composition adopted by the infant formula of the invention can be prepared by preparing various raw materials in advance to obtain the composition, and then adding the composition as one component into the infant formula, or can be prepared by adding various raw materials forming the protein composition into the infant formula respectively.
The protein composition used in the infant formula of the present invention may be obtained by mixing various raw materials. Specifically, the preparation method of the protein composition adopted by the infant formula milk powder comprises the following steps of mixing at least one of the following protein powder and/or milk powder:
(1) Whey protein powder having an alpha-whey protein content of 25% -55%, which may be referred to as whey protein powder having a low alpha-whey protein content;
(2) Whey protein powder with 75% -95% of alpha-whey protein content can be called whey protein powder with high alpha-whey protein content;
(3) Whey protein powder with a beta-casein content of 35% -70% may be referred to as whey protein powder with a low beta-casein content;
(4) Whey protein powder with the beta-casein content of 40-80% can be called whey protein powder with high beta-casein content;
(5) Whey protein powder with the protein content of 60% -95%;
(6) Milk powder (preferably skimmed milk powder) with protein content of 15% -50%.
According to a specific embodiment of the present invention, the low alpha-lactalbumin content whey protein powder (1) used in the preparation of the protein composition preferably has an alpha-lactalbumin content of 30% to 50%, more preferably 35% to 45%, even more preferably 38% to 42%.
According to a specific embodiment of the present invention, the high alpha-lactalbumin content whey protein powder (2) used in the preparation of the protein composition preferably has an alpha-lactalbumin content of 80% to 95%, more preferably 85% to 95%, even more preferably 90% to 95%.
According to a specific embodiment of the present invention, the low beta-casein content whey protein powder (3) used in the preparation of the protein composition preferably has a beta-casein content of 40% to 65%, more preferably 45% to 60%, even more preferably 50% to 55%.
According to a specific embodiment of the present invention, the high beta-casein content whey protein powder (4) used in the preparation of the protein composition preferably has a beta-casein content of 45-80%, more preferably 50-75%, even more preferably 55-70%, even more preferably 60-65%.
According to a specific embodiment of the present invention, the whey protein powder (5) used in the preparation of the protein composition preferably has a protein content of 65% to 90%, more preferably 70% to 85%, still more preferably 75% to 80%.
According to a specific embodiment of the present invention, preferably, the milk powder (6) used in the preparation of the protein composition has a protein content of 20% to 45%, more preferably 25% to 40%, still more preferably 30% to 35%.
The specific content ranges of the low-alpha-lactalbumin content whey protein powder (1), high-alpha-lactalbumin content whey protein powder (2), low-beta-casein content whey protein powder (3), high-beta-casein content whey protein powder (4), whey protein powder (5) and milk powder (6) listed above may be used in any combination and are not limited to the combinations specifically listed above.
According to a specific embodiment of the present invention, preferably, the method of preparing a protein composition comprises mixing at least one of the following protein powders and/or milk powders:
whey protein powder having an alpha-lactalbumin content of 41%, such as products from danish alara company;
whey protein powder having an alpha-lactalbumin content of 92.3%, such as the product of the company An Gepu in america;
whey protein powder with a beta-casein content of 53%, such as the product of the company Ireland Kerry;
whey protein powder having a beta-casein content of 63.2%, such as products of danish alaa company;
concentrated whey protein powder (WPC 80) with a protein content of 80%, such as the product of wheelco company, germany;
skim milk powder with a protein content of 33.5%, such as a constant natural group product.
According to a specific embodiment of the present invention, in the infant formula, the content of α -lactalbumin and β -casein may be controlled in different ranges, based on 100% of total protein, wherein the content of α -lactalbumin ranges from c to 50.5%, the content of β -casein ranges from d to 35.0%, and the content of α -lactalbumin and β -casein may be selected separately or cooperatively (i.e., the content of α -lactalbumin ranges from a to 50.5%, and the content of β -casein ranges from b to 35.0%), wherein c is any value, preferably an integer, between 13.0 to 50.5%, 15.0 to 50.5%, 17.0 to 50.5%, 19.0 to 50.5%, 21.0 to 50.5%, 23.0 to 50.5%, 25.0 to 50.5%, 27.0 to 50.5%, 29.0 to 50.0%, 31.0 to 35.0%, 31.0 to 50.5%, 15.0 to 50.5%, 17.0 to 50.0, 15.0 to 50.5%, 17.0 to 50.0% and so on; d is any number between 15.0 and 35.0, preferably an integer, i.e. the content of beta-casein may range from 17.0% to 35.0%, from 19.0% to 35.0%, from 21.0% to 35.0%, from 23.0% to 35.0%, from 25.0% to 35.0%, from 27.0% to 35.0%, from 29.0% to 35.0%, from 31.0% to 35.0%, from 33.0% to 35.0%, etc. The above-mentioned content ranges of α -lactalbumin and β -casein may be combined or included in the numerical ranges within the above ranges, for example: based on 100% of the total protein content of the infant formula, the infant formula contains 15.0% -32.0% of alpha-casein and 26.0% -32.0% of beta-casein, or the infant formula contains 15.0% -32.0% of alpha-casein and 29.0% -32.0% of beta-casein, or the infant formula contains 16.0% -32.0% of alpha-casein and 20.0% -32.0% of beta-casein, or the infant formula contains 16.0% -32.0% of alpha-casein and 26.0% -32.0% of beta-casein, or the infant formula contains 16.0% -32.0% of alpha-casein and 29.0% -32.0% of alpha-casein, or the infant formula contains 21.0% -32.0% of alpha-casein and 29.0% -32.0% of beta-casein, or the infant formula contains 21.0% -32.0% -0% of alpha-casein and 29.0% -32.0% of beta-casein, alternatively, the infant formula contains 29.0% -32.0% of alpha-lactalbumin and 29.0% -32.0% of beta-casein, or the infant formula contains 29.0% -32.0% of alpha-lactalbumin and 32.0% of beta-casein. The infant formula contains other types of proteins besides alpha-lactalbumin and beta-casein.
According to the specific embodiment of the invention, in the infant formula, the content of whey protein and casein can be controlled in different ranges based on 100% of total protein content: preferably, the content of whey protein in the infant formula milk powder is controlled to be 55.0-90.0%, and the content of casein is controlled to be 10.0-45.0%; more preferably, the content of whey protein in the infant formula is controlled to be 55.0-80.0%, and the content of casein is controlled to be 20.0-45.0%; further preferably, the whey protein content in the infant formula is controlled to be 55.0% -70.0%, and the casein content is controlled to be 30.0% -45.0%; further preferably, the whey protein content in the infant formula is controlled to be 55.0% -65.0%, and the casein content is controlled to be 35.0% -45.0%. Wherein the sum of the contents of whey protein and casein is not required to be 100%.
According to a specific embodiment of the present invention, preferably, the total protein content in the infant formula of the present invention is 10-23g/100g; whey protein accounts for 38-70% of total protein; the fat content is 15-29g/100g; the linoleic acid content is 1800-5000mg/100g; the alpha-linolenic acid content is 200-500mg/100g; dietary fibre content of 0.95-6.3g/100g (preferably, the dietary fibre comprises galacto-oligosaccharides and fructo-oligosaccharides); the carbohydrate content is 50-58g/100g.
According to a specific embodiment of the present invention, preferably, the protein source (i.e., the raw material providing the total protein) of the infant formula of the present invention comprises one or more of milk, whole milk powder, skim milk powder, whey protein powder, desalted whey powder, and a combination of two or more thereof; wherein the protein composition may comprise raw material alpha-whey protein powder added for fortifying alpha-whey protein, and raw material beta-casein powder added for fortifying beta-casein or the protein composition capable of improving the protein digestion performance in infant formula according to the invention.
According to a specific embodiment of the present invention, preferably, the infant formula of the present invention contains about 13.0% to 50.5% of alpha-lactalbumin and about 15.0% to 35.0% of beta-casein, based on 100% total protein content of the milk powder. In addition, the proportion of whey protein to total protein is generally controlled to 40% -70%.
According to a specific embodiment of the present invention, preferably, the raw materials include, based on 1000 parts by weight of infant formula: 800-3500 parts of raw milk and 0-400 parts of skimmed milk powder; some or all of the milk, skim milk powder may be replaced with whole milk powder, skim milk of comparable protein content.
According to a specific embodiment of the present invention, preferably, the raw materials of the infant formula of the present invention further comprise one or more of whey protein powder (e.g. whey protein powder WPC 80%, whey protein powder WPC 34%, etc.), desalted whey powder (e.g. desalted whey powder D70, D90, etc.), preferably desalted whey powder and/or whey protein powder (e.g. whey protein powder WPC 80% and/or whey protein powder WPC 34%) added for fortifying whey protein (i.e. as an ingredient of a protein composition); and the raw material alpha-whey protein powder is further added for the alpha-whey protein in the fortified product, and the raw material beta-casein powder is further added for the beta-casein in the fortified product.
According to a specific embodiment of the present invention, preferably, the protein composition is composed of at least one of the following protein powders and/or milk powders: whey protein powder with the content of alpha-whey protein of 25% -95%, whey protein powder with the content of beta-casein of 35% -80%, whey protein powder with the content of protein of 60% -95%, and milk powder (preferably skimmed milk powder) with the content of protein of 15% -50%;
more preferably, the protein composition is composed of at least one of the following protein powders and/or milk powders:
(1) Whey protein powder with the alpha-whey protein content of 25% -55%;
(2) Whey protein powder with 75% -95% of alpha-whey protein content;
(3) Whey protein powder with the content of beta-casein of 35-70%;
(4) Whey protein powder with the content of beta-casein of 40% -80%;
(5) Whey protein powder with the protein content of 60% -95%;
(6) Milk powder (preferably skimmed milk powder) with protein content of 15% -50%.
According to a specific embodiment of the present invention, preferably, the raw materials include, based on 1000 parts by weight of infant formula: 0-170 parts of whey protein powder, 25-400 parts of desalted whey powder, 0-55 parts of alpha-whey protein powder and 0-45 parts of beta-casein powder.
According to a specific embodiment of the present invention, preferably the raw material providing fat to the infant milk powder comprises, in addition to the milk fat-containing base raw material (e.g. raw milk, skim milk powder as described above) or anhydrous cream, vegetable oil or OPO structured fat, i.e. the source of fat of the infant formula comprises milk fat and/or anhydrous cream; preferably also vegetable oils and/or OPO structured fats.
According to a specific embodiment of the present invention, preferably, the vegetable oil as a raw material for providing fat may include one or more of sunflower oil, corn oil, soybean oil, canola oil, coconut oil, palm oil, walnut oil, preferably, one or more of sunflower oil, corn oil, and soybean oil. The addition of these vegetable oils provides on the one hand a fatty component to the product and on the other hand linoleic acid, while also providing alpha-linolenic acid (preferably the alpha-linolenic acid content in the infant formula of the invention is 200-500mg/100 g). In addition, the fat-providing raw material may optionally include a raw material OPO structured fat added for providing 1, 3-dioleoyl-2-palmitoleic acid triglyceride. Since the purity of the OPO structural fat raw materials sold in the market at present is different, namely the content of the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride is different, and is usually about 40% -70%, in the invention, the term "1, 3-dioleoyl-2-palmitic acid triglyceride" is adopted when describing the effective component, and the common name "OPO structural fat" is adopted when describing the infant formula milk powder raw materials for providing the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride. The specific addition amount of OPO structural fat can be converted according to the content requirement of the 1, 3-dioleoyl-2-palmitoyl triglyceride in the infant formula milk powder. More preferably, the infant formula comprises the following raw materials in parts by weight: 0-80 parts by weight of sunflower seed oil; corn oil 0-40 weight portions; 0-80 parts by weight of soybean oil; 0-140 parts by weight of OPO structural fat; 0-4 parts of anhydrous cream.
According to a specific embodiment of the present invention, preferably, the contents of linoleic acid and α -linolenic acid in the sunflower seed oil are respectively 7.6-8.9% and 0.25-0.38%; the content of linoleic acid and alpha-linolenic acid in the corn oil is 53.0-56.20 percent and 0.9-1.6 percent respectively; the contents of linoleic acid and alpha-linolenic acid in the soybean oil are respectively 50.0-53.5% and 7.6-9.6%; the contents of linoleic acid and alpha-linolenic acid in the OPO structural fat are respectively 5.9-6.3 percent and 0.4-0.62 percent; the contents of linoleic acid and alpha-linolenic acid in the canola oil are 16-19% and 8.0-10.6% respectively; the contents of linoleic acid and alpha-linolenic acid in the coconut oil are respectively 1-3% and 0-1%; the effective content of the 1, 3-dioleoyl-2-palmitic acid triglyceride in the OPO structural fat raw material is 40-70%.
According to a specific embodiment of the present invention, the infant formula of the present invention has a carbohydrate derived in part from lactose-containing base stock such as milk, whole milk powder and/or skim milk powder, etc., and additionally lactose stock should be added to provide the carbohydrate. That is, in the infant formula of the present invention, the raw material for providing carbohydrate includes lactose as a raw material in addition to lactose as a base raw material. Preferably, the infant formula of the invention comprises the following raw materials in parts by weight: 125-550 (preferably 125-325) parts by weight of lactose. The specific addition amount of lactose may be adjusted within the range so that the carbohydrate content of the infant formula of the present invention is 50-58g/100g.
According to a specific embodiment of the present invention, the raw materials of the infant formula of the present invention may further include one or a combination of two or more of DHA, ARA, nucleotide, lactoferrin, and the like. Preferably, the infant formula of the invention comprises the following raw materials in parts by weight: 2-15 (preferably 8-15) parts by weight of DHA, 3-22 parts by weight of ARA, 0-1.4 parts by weight of lactoferrin and 0-0.7 parts by weight of nucleotide.
According to the specific embodiment of the invention, the raw materials of the infant formula of the invention can also comprise compound nutrients comprising calcium powder, vitamins and minerals. The compound nutrient is a combination of nutrient components meeting the national standard, and different addition amounts are used according to different formulas. Preferably, the infant formula milk powder comprises the following raw materials in parts by weight: 7-22 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals. More preferably, the compound nutrients are added at least in the form of compound vitamin packs, calcium powders, mineral nutritional packs. Specifically, the compound nutrient is preferably added in the form of the following nutritional packages:
1) The compound vitamin nutrition package comprises the following components in each gram of compound vitamin nutrition package:
Taurine: 140-340mg
Vitamin a: 1700-5800. Mu.gRE
Vitamin D:25-70 mug
Vitamin B1:3000-6800 mug
Vitamin B2:3500-6900 mug
Vitamin B6:2400-4000 μg
Vitamin B12:8-20 mug
Vitamin K1:200-700 mug
Vitamin C:155-700mg
Vitamin E:10-70mg alpha-TE
Nicotinamide: 10000-41550 mug
Folic acid: 500-920 μg
Biotin: 100-245 mug
Pantothenic acid: 7100-25230 μg
Inositol: 0-250mg
L-carnitine: 0-60mg
2) The mineral substance two-nutrition package comprises the following components in each gram of the mineral substance two-nutrition package:
calcium: 300-455mg
Phosphorus: 75-150mg
3) The mineral substance-nutrition package comprises the following components in each gram of the mineral substance-nutrition package:
iron: 40-110mg
Zinc: 23-90mg
Copper: 2600-4180 μg
Iodine: 500-995 μg
Selenium: 0-200 mu g
Manganese: 0-579 mug
4) The compound magnesium chloride nutrition package comprises the following components in per gram:
magnesium: 80-170mg
5) The compound potassium chloride nutrition package comprises the following components in per gram:
potassium: 400-580mg;
6) The choline chloride nutrition packet comprises the following components in per gram:
choline: 300-950mg;
preferably, based on 1000 parts by weight of infant formula milk powder, the addition amount of the compound vitamin nutrition package is 2-4 parts by weight, the addition amount of the mineral two nutrition packages is 2-12 parts by weight, the addition amount of the mineral one nutrition package is 0.5-3 parts by weight, the addition amount of the compound magnesium chloride nutrition package is 0-2 parts by weight, the addition amount of the compound potassium chloride nutrition package is 0-4.5 parts by weight, the addition amount of the choline chloride nutrition is 0-2 parts by weight, and the base material of each nutrition package is preferably lactose or L-sodium ascorbate.
The component contents of the compound nutrient are the content of nutrient components in other raw materials of the milk powder, such as calcium powder (calcium carbonate) in mineral II, for enhancing the addition amount of the nutrient substances, and each 1000 kg of the milk powder contains' calcium: 1300-1600g "means that to fortify the calcium element in the product, mineral di (e.g. calcium carbonate) nutritional packages are added based on 1000 kg weight of milk powder, wherein the weight of the calcium element is 1300-1600g.
According to a specific embodiment of the present invention, the raw material of the infant formula according to the present invention may further comprise a probiotic, preferably the probiotic is bifidobacteria. More preferably, the bifidobacterium is added in an amount of 0.1 to 0.2 parts by weight based on 1000 parts by weight of the infant formula; and still more preferably 0.18 to 0.2 parts by weight. More preferably, the content of bifidobacteria per part by weight of the bifidobacteria powder is 3X 10 10 CFU or more.
According to a specific embodiment of the present invention, the infant formula raw materials of the present invention preferably comprise:
7-22 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals;
it can be understood that the specific dosage of each raw material in the infant formula of the invention is determined by adjusting on the premise of meeting the index requirement of the infant formula. In the infant formula of the invention, the product performance indexes which are not specified or listed in detail are executed according to the national standard of infant formula or prepared milk powder and the regulations of related standards and regulations.
In the infant formula milk powder, all raw materials are commercially available, and the raw materials are selected to meet the requirements of related standards, wherein the protein composition meets the requirements of the invention. In addition, the compound nutrient can also be self-compounded. The invention adopts 'compound' for convenience of expression, and does not mean that all components in the compound are mixed together and then applied. All raw materials should be added and used on the premise of meeting related regulations.
According to a specific embodiment of the present invention, the infant formula of the present invention is preferably a formula suitable for infants and children between 0 and 7 years old, which formula has better protein digestion and absorption.
On the other hand, the invention also provides a method for preparing the infant formula milk powder, and the preparation process flow mainly comprises the following steps: proportioning, homogenizing, concentrating, sterilizing, spray drying and dry mixing to obtain the finished product. Specifically, the preparation method of the infant formula milk powder comprises the following steps:
mixing the milk, powder raw materials and melted grease raw materials subjected to rough filtration, homogenization and sterilization, and adding compound nutrients to obtain mixed feed liquid;
filtering, homogenizing, cooling, concentrating, sterilizing, spray drying, fluidized bed drying, cooling to obtain dried milk powder, mixing with DHA, ARA, lactoferrin, nucleotide and Bacillus bifidus, and sieving to obtain the infant formula milk powder.
In the above preparation method, preferably, the primary pressure of the homogenization treatment of the mixed liquor is 105.+ -. 5bar, and the secondary pressure is 32.+ -. 3bar.
In the preparation method, preferably, the concentration sterilization adopts double-effect concentration, more preferably, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; further preferably, the discharge concentrations are all 48% -52% dry matter.
In the above preparation method, preferably, the spray drying has an inlet air temperature of 165-180deg.C, an outlet air temperature of 75-90deg.C, a high pressure pump pressure of 160-210bar, and a column negative pressure of-4 mbar to-2 mbar.
In the above preparation method, preferably, the fluidized bed drying and cooling comprises two times of drying and cooling, and the temperature of the milk powder after the two times of drying and cooling is 25-30 ℃; and mixing phospholipid with carrier, heating to 60-65deg.C, and dispersing on the surface of milk powder under the action of compressed air.
According to a specific embodiment of the present invention, the preparation process of the infant formula of the present invention may comprise the following specific steps:
1) Coarse filtration of milk: after coarse filtration and degassing of the balance cylinder, the milk is preheated by a plate heat exchanger and then separated from impurities by a separator.
2) Homogenizing and sterilizing milk: part of the milk after removing the impurities enters a homogenizer for homogenization, the other part of the milk is not homogenized, the homogenized milk and the non-homogenized milk are mixed and then enter a sterilizing system for sterilization, and the sterilized milk enters a mixing tank.
3) Powder adding: the various powder raw materials are metered according to the formula and then are uniformly added into a powder preparation tank for storage through an air-assisted system.
4) Vacuum powder suction: various powder raw materials in the powder preparation tank are sucked into the mixing tank through a vacuum system.
5) Melting and oil preparing: the oil and fat specified in the formula are placed into an oil melting room according to the formula requirement, the temperature of the oil melting room is kept at 50-90 ℃, and after the oil is melted, the oil is pumped into a mixed oil storage tank according to the formula proportion requirement through an oil pump and a flowmeter.
6) And (3) storing the mixed oil: the mixed oil is stored in an oil storage tank in a heat-preserving way at 40-50 ℃ for less than 12 hours to prevent fat oxidation.
7) Weighing: and pumping the mixed oil into a mixing tank through an oil pump according to the formula requirement.
8) Nutrient dissolution and addition: respectively adding calcium powder, minerals, vitamins, respectively, dissolving with 100-200kg purified water, adding into mixing tank, and flushing the adding tank and pipeline with 100kg purified water.
9) And (3) filtering: and mixing all the raw materials in a mixing tank, and filtering the mixed feed liquid by a filter screen to remove physical impurities possibly carried in the raw materials.
10 Homogenizing: homogenizing the mixed feed liquid by a homogenizer, wherein the primary pressure is 105+/-5 bar, the secondary pressure is 32+/-3 bar, and mechanically treating the fat globules to disperse the fat globules into uniform fat globules.
11 Cooling and storing: the homogenized feed liquid enters a plate heat exchanger for cooling, the temperature is lower than 20 ℃, the homogenized feed liquid is temporarily stored in a pre-storing cylinder, the next working procedure is carried out within 6 hours, and a stirrer is started according to set requirements.
12 Concentration sterilization: during production, double-effect concentration is used, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; the discharge concentration is 48% -52% of dry matter.
13 Concentrated milk storage, pre-heating filtration, spray drying: temporarily storing the concentrated milk in a concentrated milk balance tank; preheating to 60-70deg.C by scraper preheater, filtering the preheated material by 1mm pore diameter filter, spraying with high pressure pump, drying, and agglomerating fine powder on top of tower or fluidized bed; wherein the air inlet temperature is 165-180 ℃, the air outlet temperature is 75-90 ℃, the high-pressure pump pressure is 160-210bar, and the negative pressure of the tower is-4 mbar to-2 mbar.
14 Fluidized bed drying and cooling: the milk powder from the drying tower is subjected to secondary drying by a fluidized bed (first stage) and then is cooled to 25-30 ℃ by the fluidized bed (second stage); and meanwhile, the phospholipid and the carrier are mixed and then heated to 60-65 ℃, and the phospholipid is uniformly dispersed on the surface of the milk powder under the action of compressed air, so that the granularity and the quick solubility of the powder particles are increased by agglomerating the powder particles.
15 Split charging: and weighing DHA, ARA, lactoferrin, nucleotide and bifidobacterium according to the formula requirement, sealing bags and subpackaging.
16 Dry blending): and uniformly mixing the weighed DHA, ARA, lactoferrin, nucleotide, bifidobacterium and milk powder in a dry mixer.
17 Screening powder: the granularity of the milk powder is uniform through the vibrating screen, and the powder slag is scrapped.
18 Powder discharge: and (3) receiving powder by using a sterilized powder collecting box, and conveying the powder from a powder outlet room to a powder feeding room.
19 Powder) is added: and pouring the milk powder into a powder storage tank on a size packaging machine according to the packaging requirement.
20 Packaging: nitrogen filling and packaging of an automatic 800 g packaging machine; oxygen content is lower than 1% during nitrogen filling; 900 g of iron can is automatically filled with nitrogen and packaged, and the oxygen content is lower than 5%.
21 Boxing: packaging the packaged small bags into a paper box, adding a powder spoon at the same time, and sealing by a box sealing machine.
22 Inspection of the finished product: sampling and checking the packaged product according to a checking plan.
23 Warehousing and storing: the qualified products are stored in warehouse, and the storage is required at normal temperature, and the humidity is less than or equal to 65%.
In combination, the infant formula provided by the invention has the effect of promoting protein digestion and absorption.
The technical scheme of the invention has the following beneficial effects:
(1) By adopting the technical scheme of the invention, the digestibility of whey protein in infant formula milk powder can be obviously improved.
(2) By adopting the technical scheme of the invention, more kinds of free amino acids can be released.
(3) The technical scheme of the invention can improve the release proportion of the essential amino acid EAA.
(4) By adopting the technical scheme of the invention, more small molecular peptides can be generated in the digestion process.
(5) By adopting the technical scheme of the invention, more characteristic peptide fragments can be generated.
Drawings
FIGS. 1-6 are the results of the release of small molecule peptides in an in vitro gastric digestion experiment from samples of the protein compositions of examples 1-5 and comparative example 1, respectively.
Detailed Description
The following detailed description of the preparation method of infant formula according to the present invention is provided by specific examples, which are intended to help the reader to better understand the essence and characteristics of the present invention, and are not intended to limit the scope of the present invention. The procedure not specifically identified in the examples below is generally followed by conventional procedures in the art.
Description of the raw materials of examples and comparative examples:
the skimmed milk powder is produced by constant natural group, and has protein content of 33.5%.
WPC80 is a concentrated whey protein powder with a protein content of 80% available from Wheyco, germany.
Whey protein powder with low alpha-lactalbumin content has an alpha-lactalbumin content of 41% and is available from danish alara company.
Whey protein powder with high alpha-lactalbumin content has an alpha-lactalbumin content of 92.3% and is available from us An Gepu company.
The low beta-casein content whey protein powder had a beta-casein content of 53% and was purchased from Kerry company in irish.
The high beta-casein content whey protein powder had a beta-casein content of 63.2% and was purchased from danish alaa company.
Lactose is purchased from the company Indiana USA.
Example 1
The present example provides a protein composition (sample 1) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 60% and a casein content of 40% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 2
The present example provides a protein composition (sample 2) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 60% and a casein content of 40% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 3
The present example provides a protein composition (sample 3) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 60% and a casein content of 40% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 4
The present example provides a protein composition (sample 4) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 60% and a casein content of 40% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 5
The present example provides a protein composition (sample 5) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 60% and a casein content of 40% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Comparative example 1
The present comparative example provides a protein composition (sample 6) comprising the following raw materials (in parts by weight):
160 parts of skimmed milk powder
WPC80 parts
450 parts of lactose.
The protein composition provided in this comparative example had a whey protein content of 60% and a casein content of 40% (based on 100% of the total protein content), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 6
The present example provides a protein composition (sample 7) comprising the following raw materials in parts by weight:
skimmed milk powder 230 parts
16.5 parts of whey protein powder with high alpha-whey protein content
300 parts of lactose.
The protein composition provided in this example had a whey protein content of 35% and a casein content of 65% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 7
The present example provides a protein composition (sample 8) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 35% and a casein content of 65% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Comparative example 2
The present comparative example provides a protein composition (sample 9) comprising the following components in parts by weight:
262 parts of skimmed milk powder
WPC 80.26 parts
383.5 parts of lactose.
The protein composition provided in this comparative example had a whey protein content of 35% and a casein content of 65% (based on 100% of the total protein content), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 8
The present example provides a protein composition (sample 10) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 50% and a casein content of 50% (based on 100% of total protein content), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 9
The present example provides a protein composition (sample 11) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 50% and a casein content of 50% (based on 100% of total protein content), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 10
The present example provides a protein composition (sample 12) comprising the following raw materials (in parts by weight):
The protein composition provided in this example had a whey protein content of 50% and a casein content of 50% (based on 100% of total protein content), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Comparative example 3
The present comparative example provides a protein composition (sample 13) comprising the following raw materials (in parts by weight):
202 parts of skimmed milk powder
WPC80 parts
418 parts of lactose.
The protein composition provided in this comparative example had a whey protein content of 50% and a casein content of 50% (based on 100% of the total protein content), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 11
The present example provides a protein composition (sample 14) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 70% and a casein content of 30% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Example 12
The present example provides a protein composition (sample 15) comprising the following raw materials (in parts by weight):
the protein composition provided in this example had a whey protein content of 70% and a casein content of 30% (based on 100% of total protein), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
Comparative example 4
The present comparative example provides a protein composition (sample 16) comprising the following raw materials (in parts by weight):
121 parts of skimmed milk powder
WPC 80.5 parts
525 parts of lactose.
The protein composition provided in this comparative example had a whey protein content of 70% and a casein content of 30% (based on 100% of the total protein content), and the total protein content, the content and the ratio of α -lactalbumin, the content and the ratio of β -casein, and the like are shown in table 1.
TABLE 1
The protein digestion conditions of the samples provided in examples 1 to 12 and comparative examples 1 to 4, including degradation conditions of whey protein in the stomach, release conditions of amino acids after digestion in the small intestine, and peptide production effects were evaluated by simulating the process of digestion in the stomach and small intestine of infants in vitro.
1. In vitro gastric digestion experiments
1. Sample preparation and processing
The method of the in vitro simulated gastric digestion test of the sample refers to the method of Dupont and is modified to a certain extent, and is specifically as follows:
(1) Preparing a milk sample: and (3) regulating the concentration of the sample to 10mg/mL by deionized water according to the protein content measurement result, preparing a 50mL milk sample, adding HCl with the concentration of 1mol/L to regulate the pH value to 4.0, and preheating in a water bath at 37 ℃.
(2) Preparation of simulated gastric fluid: 4.33mg pepsin and 23.755mg gastric lipase are weighed, 45mL of NaCl solution with the concentration of 0.15M is added, the pH is adjusted to 4.0 by using 1M hydrochloric acid, the volume is fixed to 50mL to form simulated gastric juice, the pepsin concentration in the system is 113.75U/mL, and the final gastric lipase concentration is 21U/mL.
(3) Gastric digestion experimental procedure: 50mL of the milk sample was added to 50mL of simulated gastric fluid in an enzyme reactor (37 ℃) and samples were taken at 0h and 3h of digestion, 20mL each, and the reaction was stopped by adjusting the pH of the sample to 7.0 with 1M NaOH.
The samples of examples 1-12 and comparative examples 1-4 were each pretreated in the manner described above to obtain gastric juice samples each at a different digestion time.
2. Semi-quantitative analysis of digestive juice
(1)SDS-PAGE：
Samples taken at 0h and 3h respectively were combined with deionized water 1:1 dilution with 2 Xsample buffer (pre-mixed protein sample buffer from Bio-rad) according to 1:1, and boiling the mixture after uniform mixing, wherein the loading amount is 5 mu L.
The following electrophoresis and staining methods were used:
the concentration of the separation gel is 12% (w/v), the concentration gel is 5% (w/v), and the specific formula is shown in Table 2; constant voltage, 150V of concentrated gel voltage and 300V of separation gel in the electrophoresis process; the dyeing agent is 0.1% coomassie brilliant blue R-250 solution, and the decoloring agent is a mixed solution prepared from ethanol and acetic acid; after the gel runs out, the gel is gently removed, after the electrophoresis buffer solution is washed away, the gel is dyed for 2 hours by using coomassie brilliant blue dyeing solution on a horizontal shaking table, and then the gel is decolorized by using a decolorizing solution until the band is clearly visible.
TABLE 2 gel composition of SDS-PAGE
| Composition of the components | 12% separating gel (mL) | 5% concentrated glue (mL) |
| Distilled water | 10.2 | 5.8 |
| 30％Acr-Bis(29:1) | 12.0 | 1.7 |
| Separating gel buffer (4X) | 7.5 | - |
| Concentrated glue buffer (4X) | - | 2.5 |
| 10% gel polymerization catalyst | 0.3 | 0.1 |
| TEMED | 0.012 | 0.01 |
(2) Semi-quantitative analysis of protein content change: semi-quantitative analysis of the trend of the change in the relative content of milk proteins was performed on the electrophoresis strips of the gastric digest samples of examples 1-5 and comparative example 1 using the Tanon Image electrophoresis Image processing software, with the relative content of whey proteins for the 0min sample set to 100% and the relative content of proteins at other time points as the ratio of the time point to the strip area of 0 min.
2. In vitro gastric and intestinal digestion experiments
1. Sample preparation and processing
(1) Preparing a milk sample: the sample is adjusted to 10mg/mL by deionized water to prepare 50mL milk sample, HCl with 1mol/L concentration is added to adjust the pH value to 4.0, and the mixture is preheated in a water bath kettle at 37 ℃.
(2) Preparation of simulated gastric fluid: 4.33mg pepsin and 23.755mg gastric lipase are weighed, 45mL of NaCl solution with the concentration of 0.15M is added, the pH is adjusted to 4.0 by using 1M hydrochloric acid, the volume is fixed to 50mL to form simulated gastric juice, the pepsin concentration in the system is 113.75U/mL, and the final gastric lipase concentration is 21U/mL.
(3) Preparation of simulated intestinal juice: 0.324mg trypsin, 0.988mg chymotrypsin, 2.27g pancreatic lipase and 0.66g bile salt are weighed, 248 mL of 0.15M NaCl solution is added, 1M NaOH is used for adjusting the pH to 6.5, and the volume is fixed to 250mL to form simulated intestinal juice.
(4) Gastrointestinal digestion experiment procedure: adding 25mL of milk sample into 25mL of simulated gastric fluid in an enzyme reactor (37 ℃) to perform gastric digestion for 2 hours, then adding the milk sample into simulated intestinal fluid to perform digestion, sampling at 0, 2 hours of stomach, 0.25 hours of intestine, 1 hour of intestine and 2 hours of intestine respectively, and taking 20mL of milk sample each time, wherein the sampling adopts an enzyme preparation to terminate reaction, so as to obtain different digestive fluid samples. Taking the example of "intestinal 1h", it means that the sample is digested in simulated gastric fluid for 2h and then digested in simulated intestinal fluid for 1h again.
2. Determination of free amino acids
Taking 1mL of digestion liquid sample at each time point, diluting with 10g/100mL of TCA in equal volume, shaking uniformly, performing ultrasonic treatment for 30min, and standing for more than 2 h; centrifuging the sample at 10000rpm for 30min; after passing the supernatant through a 0.45 μm membrane, 400. Mu.L of the supernatant was packed in a liquid phase vial.
The amino acid content of the samples was analyzed using HPLC detection using a high-phase liquid phase system equipped with a sodium cation exchange amino acid analysis column (4×150mm, pickering, USA) and a post-phthaloyl column derivative system (Pickering, USA).
Chromatographic conditions: angilent Hypersil ODS column (5 μm,4.0 mm. Times.250 mm); column temperature is 40 ℃; mobile phase a (ph=7.2): 27.6mmol/L sodium acetate-triethylamine-tetrahydrofuran (volume ratio 500:0.11:2.5), mobile phase B (ph=7.2): 80.9mmol/L sodium acetate-methanol-acetonitrile (volume ratio 1:2:2); gradient elution is adopted, and the elution procedure is as follows: 0min,8% b;17min,50% B;20.1min,100% b;24.0min,0% b; the flow rate of the mobile phase is 1.0mL/min; an ultraviolet detector (VWD) detection wavelength of 338nm, proline at 262 nm; the amino acid content is quantified by an external standard method.
3. Determination of peptide fragments after digestion
The ultrafiltration tube is centrifuged for 20min at 5000g by PBS buffer solution, and the step is repeated for three times to achieve the aim of cleaning; changing a collecting pipe, loading a sample into an ultrafiltration pipe, centrifuging at 5000g for 20min, performing centrifugal ultrafiltration on the sample, and collecting a flow-through liquid; cleaning the ultrafiltration tube by using 2-3mL of PBS buffer solution, combining with the flow-through solution in the third step, and then pumping out; selecting proper desalting column to remove salt, and collecting sample Using Orbitrap Fusion TM Tribrid TM And detecting by a three-in-one mass spectrometer.
(1) High performance liquid phase the drained peptide samples were reconstituted with mobile phase A (2% ACN,0.1% FA), centrifuged at 20,000g for 10 min, and the supernatants were sampled. Separation was performed by Thermo company UltiMate 3000 UHPLC. The sample was first run into a trap column for enrichment and desalting, then serially connected to a self-contained C18 column (75 um inside diameter, 3 μm column > particle size, 25cm column length) and separated at a flow rate of 300nl/min by the following effective gradient: 0-5min,5% mobile phase B (98% acn,0.1% FA); 5-45min, the mobile phase B is linearly increased from 5% to 25%;45-50min, mobile phase B rises from 25% to 35%;50-52min, mobile phase B rises from 35% to 80%;52-54min,80% mobile phase B;54-60min,5% mobile phase B. The nanoliter liquid phase separation end is directly connected with the mass spectrometer.
(2) Mass spectrometry detection peptide fragments separated in liquid phase were ionized by a nanoESI source and entered into a tandem mass spectrometer Q-exact HF X (Thermo Fisher Scientific, san Jose, CA) for DDA (data-dependent acquisition) mode detection. Main parameter setting: the ion source voltage is set to 2kV; the scanning range of the primary mass spectrum is 350-1500m/z; resolution setting 60000; the initial m/z of the secondary mass spectrum is fixed to be 100; resolution 15000. The screening conditions of the secondary fragmentation parent ions are as follows: charge 2+ to 6+, parent ion with peak intensity exceeding 10,000 intensity row top 30. Ion fragmentation mode is HCD, fragment ions are detected in Orbitrap. The dynamic exclusion time was set to 30s. The AGC is set to: primary 3E6, secondary 1E5.
(3) And (3) carrying out data information analysis on the data of the machine, using an Andromeda engine integrated with the MaxQuant to complete identification, carrying out quantitative analysis on the MaxQuant according to the information such as peak intensity, peak area, liquid chromatography retention time and the like of peptide fragments related to primary mass spectrum, and carrying out a series of statistical analysis and quality control. Filtering is completed at the spectrogram level with PSM-level FDR < = 1%, and further filtering is performed at the Peptide fragment level Peptide-level FDR < = 1%, so as to obtain a significance identification result. The precursor proteins were then annotated for GO, COG, path functions based on the identification. Based on the quantitative result, calculating the difference peptide fragments among different comparison groups, and finally, carrying out functional analysis on the precursor proteins corresponding to the difference enrichment peptide fragments.
Experimental results and analysis:
1. whey protein digestibility
Whey protein digestion performance data of in vitro gastric digestion experiments of the samples of examples 1-7, 9-10, 12 and comparative examples 1-4 are shown in Table 3 and FIG. 1.
TABLE 3 Table 3
As can be seen from the contents of table 3: in the digestion process of the in vitro stomach, the comparison with the samples of comparative examples 1 to 4 respectively shows that the samples of examples 1 to 7, 9 to 10 and 12 of the present invention have a relatively low residual whey protein ratio at different digestion time points, which means that the digestion of whey proteins in the in vitro stomach of samples 1 to 5, 7 to 8, 11 to 12 and 15 is increased, i.e. the protein compositions of examples 1 to 7, 9 to 10 and 12 have whey protein digestion performance superior to that of comparative example 1, especially the effect of the corresponding samples of examples 5 and 6 is most prominent.
2. Free amino acids
The types of free amino acids released by the samples of the protein compositions of examples 1-12 and comparative examples 1-4 in an in vitro gastric digestion experiment include Lys, phe, met, trp, thr, ile, leu, val, his, cys-s, tyr, asp, glu, ser, gly, arg, ala, pro, EAA, NEAA, TAA, etc., wherein Lys, phe, met, trp, thr, ile, leu, val, his, EAA is an essential amino acid.
3. Free essential amino acid EAA
Experimental data for the free essential amino acids EAA released by the samples of examples 1-12 and comparative examples 1-4 in an in vitro gastrointestinal digestion experiment, i.e. the percentage of free essential amino acids EAA in total free amino acids, are shown in table 4. Wherein:
EAA% = free essential amino acids/total free amino acids x 100%
Fold increase in EAA% post digestion = (post digestion EAA% -pre digestion EAA%)/pre digestion EAA%
TABLE 4 Table 4
As can be seen from the data in table 4: in the digests obtained by in vitro gastrointestinal digestion, the protein compositions of examples 1-12 showed a greater fold increase in the release of the essential amino acids EAA after digestion compared to the corresponding comparative examples 1-4, indicating that the technical solution provided by the present invention is capable of producing more beneficial essential amino acids during digestion.
4. Small molecule peptide (short peptide)
The ratio data of the small molecule peptides released In the In vitro gastrointestinal digestion experiments of the samples of the protein compositions of examples 1 to 5 and comparative example 1 are shown In Table 5 and FIGS. 1 to 6, wherein FIGS. 1 to 5 correspond to the samples of examples 1 to 5, respectively, and FIG. 6 corresponds to the sample of comparative example 1 as a control, wherein n-0 represents the data when sample n is not digested, gn-120 represents the data when sample n is digested In simulated gastric fluid for 120min, in-120 represents the data when sample n is first digested In simulated gastric fluid for 120min and then digested In simulated intestinal fluid for 120min, and n is 1, 2, 3, 4, 5, 6, and sample n refers to sample 1, sample 2, sample 3, sample 4, sample 5, and sample 6.
Table 5 (unit: percent (%) increase)
As can be seen from the data of table 5 and the curves of fig. 1-6: the increase in the small molecule peptides (0<X.ltoreq.10) was significantly higher for the samples of the protein compositions of examples 1-5 than for the control sample (sample 6 of comparative example 1) after in vitro gastrointestinal digestion. It is believed that the protein is gradually degraded and differentiated into small molecules in the digestive tract, and that the lower the molecular weight of the peptide fragment, the more favorable the absorption is, and from this point, the protein compositions of examples 1 to 5 are also proved to have good digestion properties. In particular, the peptide fraction small molecule ratio of the samples corresponding to examples 2 to 5 was significantly higher than that of comparative example 1, which revealed that excellent results in terms of release of small molecule peptide could be obtained when the content of α -lactalbumin was controlled to 21% to 32% and the content of β -casein was controlled to 26% to 32%.
5. Characteristic peptide fragment
The data for the characteristic peptide fragments released by the samples of the protein compositions of examples 1-5 in the in vitro gastrointestinal digestion experiments are shown in Table 6.
TABLE 6
| Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | |
| Sample 1 | Sample 2 | Sample 3 | Sample 4 | Sample 5 | |
| F.QINNKIW.C | 2.05E+06 | 3.24E+06 | 4.75E+05 | 1.27E+07 | 7.57E+06 |
| A.IVENNESTEYGLF.Q | 4.99E+06 | 2.19E+06 | 2.82E+06 | 7.76E+06 | 2.02E+06 |
| K.GYGGVS.L | 2.37E+06 | 4.07E+06 | 5.64E+06 | 4.49E+06 | 5.80E+06 |
| K.FLDDDLTDD.I | 1.14E+06 | 6.07E+05 | 4.66E+05 | 2.46E+06 | 1.19E+06 |
| V.MFPPQ.S | 2.27E+08 | 6.24E+08 | 9.43E+08 | 9.62E+08 | 7.86E+08 |
| L.TQTPVVVPP.F | 1.17E+08 | 2.48E+08 | 3.39E+08 | 3.90E+08 | 3.49E+08 |
| L.VYPFPGPIP.N | 6.41E+07 | 1.32E+08 | 1.43E+08 | 1.36E+08 | 1.81E+08 |
| L.PQNIPPL.T | 1.18E+08 | 1.78E+08 | 1.90E+08 | 1.21E+08 | 1.29E+08 |
| Q.TLALPPQP.L | 1.58E+07 | 3.07E+07 | 4.38E+06 | 1.02E+08 | 8.58E+07 |
Casein is rapidly hydrolyzed in the stomach to become a polypeptide fragment, more peptide fragments are released in the small intestine, and peptide fragments derived from alpha-lactalbumin and beta-lactoglobulin are also reported to be found in the digestive tract many times, and further research shows that the peptide fragments released from the milk proteins have important physiological functions such as regulating immune functions, lowering blood pressure, inhibiting bacteria, promoting mineral absorption, regulating blood glucose metabolism, regulating appetite, opioid peptides playing morphine-like functions, and resisting oxidation, etc. According to Alice et al, a number of peptides having different physiological functions, such as opioid peptides derived from beta-casein, ACE inhibiting peptides derived from alpha-whey protein, etc., were found in the body fluid of the human body after ingestion of the milk product. Analysis by Karima et al using LC-MS/MS showed that after sucking milk powder for 30 minutes, 90 minutes and 120 minutes, a large amount of polypeptide derived from beta-casein (74-91) was detected in jejunum and ileum, respectively, and these peptides had immunoregulatory and hypotensive functions; 30 minutes and 90 minutes after ingestion, 7-15 amino acid peptides derived from β -lactoglobulin were detected in jejunum, whereas large peptides derived from β -lactoglobulin were found in ileum containing 23 amino acids and 40 amino acids, respectively, which peptides were associated with proliferation and cytokine release of spleen cells, presumably having the function of modulating immunity.
It was found by breast milk studies that there are a large number of peptide fragments in breast milk, and more peptide fragments are released as digestion progresses in the infant's digestive tract. In vitro digestion studies have shown that beta-casein in breast milk is the main source of functional peptide fragments, 305 peptide fragments of this source are detected in undigested breast milk, and the number of peptide fragments rises to 646 after digestion; for alpha-lactalbumin, there is a similar phenomenon, and there is no report of the source peptide fragment found in undigested breast milk, whereas 58 peptide fragments are reported after digestion.
Comparing the peptides produced after in vitro gastric digestion to the samples of the protein compositions of examples 1-5 produced some characteristic peptides which were not found in sample 6 (comparative example 1) as a control, further analysis of the function of these peptides indicated that the characteristic peptides produced after digestion were believed to exert the following physiological functions in vivo: anti-inflammatory reaction, resisting invasion of external pathogenic bacteria, in vivo signal transmission, etc.
From the above experimental results, it can be seen that:
the samples of examples 1-7, 9-10, 12 of the present invention all had a relatively low proportion of whey protein remaining at different digestion time points, and the protein compositions of these examples had excellent whey protein digestion performance, particularly as shown in examples 5 and 6.
Samples of the protein compositions of examples 1-12 were able to release a variety of free amino acids in vitro gastric digestion experiments.
In particular, the protein compositions of examples 1-12 were able to release a large amount of essential amino acids after digestion, with a large fold increase in EAA release, indicating that the protein compositions of examples 1-12 were able to produce more beneficial essential amino acids during digestion.
The protein compositions of examples 1 to 5 also demonstrated good digestibility from the fact that the increased proportion of small molecule peptides (0<X.ltoreq.10) in the samples of the protein compositions of examples 1 to 5 was significantly higher after in vitro gastrointestinal digestion than in the control sample (sample 6 of comparative example 1). In particular, the peptide fraction small molecule ratio of the samples corresponding to examples 2 to 5 was significantly higher than that of comparative example 1, which revealed that excellent results in terms of release of small molecule peptide could be obtained when the content of α -lactalbumin was controlled to 21% to 32% and the content of β -casein was controlled to 26% to 32%.
Samples of the protein compositions of examples 1-5 were able to produce characteristic peptide fragments during digestion, which were not found in sample 6 (comparative example 1) as a control, and further analysis of the function of these peptide fragments indicated that the characteristic peptides produced after digestion were believed to exert the following physiological functions in vivo: anti-inflammatory reaction, resisting invasion of external pathogenic bacteria, in vivo signal transmission, etc.
Example 13
The embodiment provides infant formula, which contains a protein composition capable of improving the protein digestion performance in the infant formula, and the total weight of the infant formula is 1000 kg, and the infant formula comprises the following raw materials:
raw milk 850 kg, protein composition 679 of example 11.4 kg, 25 kg of desalted whey powder D90, 40 kg of corn oil, 50 kg of soybean oil, 140 kg of OPO structural fat, 17 kg of fructo-oligosaccharide powder, 40 kg of galacto-oligosaccharide syrup, 21 kg of compound nutrient, 12 kg of DHA, 22 kg of ARA and 0.1 kg of bifidobacterium (each kg of bifidobacterium powder contains 3X 10 bifidobacterium) 10 CFU or more);
wherein the compound nutrients comprise about 3.5 kg of compound vitamin nutrition package, about 1 kg of choline chloride nutrition package, about 12 kg of mineral secondary nutrition package, about 1 kg of mineral primary nutrition package, about 1.5 kg of magnesium chloride nutrition package and about 2 kg of potassium chloride nutrition package, and the base material of each nutrition package is lactose.
The specific preparation process of the infant formula of this example is as follows:
1) Rough filtration of cow milk: the cow milk is subjected to coarse filtration and degassing by a balance cylinder, is preheated by a plate heat exchanger, and is separated from impurities by a separator.
2) Homogenizing and sterilizing cow milk: part of the milk after removing the impurities enters a homogenizer for homogenization, the other part of the milk is not homogenized, the homogenized milk and the non-homogenized milk are mixed and then enter a sterilizing system for sterilization, and the sterilized milk enters a mixing tank.
3) Powder adding: the various powder raw materials are metered according to the formula, then are added into a powder mixing tank in a unified way through an air conveying system, and are sucked into the mixing tank through a vacuum system.
4) Melting and oil preparing: the oil and fat specified in the formula are put into an oil melting room according to the formula requirement, the temperature of the oil melting room is kept at 50-90 ℃, after the oil is melted, the oil is put into a mixed oil storage tank (the temperature is 40-50 ℃ and the storage time is less than 12 hours, so that fat oxidation is prevented), and the mixed oil is pumped into the mixing tank through an oil pump according to the formula requirement.
5) Nutrient dissolution and addition: respectively dissolving calcium powder, vitamins, minerals and other nutrients in purified water, and sequentially adding into a mixing tank; and mixing all the raw materials in a mixing tank to obtain mixed feed liquid.
6) And (3) filtering: the mixed feed liquid is filtered by a filter screen to remove physical impurities possibly carried in the raw materials.
7) Homogenizing: homogenizing the mixed feed liquid by a homogenizer, wherein the primary homogenizing pressure is 105+ -5 bar, the secondary homogenizing pressure is 32+ -3 bar, mechanically treating the fat globules, and dispersing them into uniform fat globules.
8) Cooling and storing: the homogenized feed liquid enters a plate heat exchanger for cooling, the temperature is lower than 20 ℃, the homogenized feed liquid is temporarily stored in a pre-storing cylinder, the next working procedure is carried out within 6 hours, and a stirrer is started according to set requirements.
9) And (3) concentrating and sterilizing: during production, double-effect concentration is used, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; the discharge concentrations were 50% dry matter.
10 Concentrated milk storage, pre-heating filtration, spray drying: temporarily storing the concentrated milk in a concentrated milk balance tank; preheating to 60 ℃ by a scraper preheater, filtering the preheated material by a filter with the aperture of 1mm, pumping the material into a drying tower by a high-pressure pump for spray drying, and agglomerating fine powder on the top of the tower or a fluidized bed according to requirements; wherein the air inlet temperature is 180 ℃, the air exhaust temperature is 86 ℃, the pressure of the high-pressure pump is 200bar, and the negative pressure of the tower is about-4 mbar.
11 Fluidized bed drying and cooling: the powder from the drying tower is subjected to fluidized bed (primary) secondary drying and then is cooled to 30 ℃ through a fluidized bed (secondary); and meanwhile, the lecithin and the carrier are mixed and then heated to 60 ℃, and under the action of compressed air, the lecithin is uniformly dispersed on the surface of the milk powder, so that the granularity and the quick solubility of the milk powder particles are increased by agglomerating the milk powder particles.
12 Split charging: and weighing DHA, ARA or bifidobacterium according to the formula requirement, sealing bags and subpackaging.
13 Dry blending): and uniformly mixing the weighed DHA, ARA or bifidobacterium with milk powder in a dry mixer.
14 Screening powder: the granularity of the milk powder is uniform through the vibrating screen, and the powder slag is scrapped.
15 Powder discharge: and (3) receiving powder by using a sterilized powder collecting box, and conveying the powder from a powder outlet room to a powder feeding room.
16 Powder) is added: and pouring the milk powder into a powder storage tank on a size packaging machine according to the packaging requirement.
17 Packaging: 400 g of automatic packaging machine fills nitrogen for packaging. Oxygen content is lower than 1% during nitrogen filling; 900 g of iron can is automatically filled with nitrogen and packaged, and the oxygen content is lower than 5%.
18 Boxing: packaging the packaged small bags into a paper box, adding a powder spoon at the same time, and sealing by a box sealing machine.
19 Inspection of the finished product: sampling and checking the packaged product according to a checking plan.
20 Warehousing and storing: the qualified products are stored in warehouse, and the storage is required at normal temperature, and the humidity is less than or equal to 65%.
Wherein, the whey protein content of the protein composition in the infant formula obtained in the example is 70%, the casein content is 30%, and the total protein content is 100%;
the infant formula obtained in this example had a total protein content of 10.50g/100g, an alpha-lactalbumin content of 2.218g/100g and a beta-casein content of 3.156g/100g.
Example 14
The embodiment provides infant formula, which contains a protein composition capable of improving the protein digestion performance in the infant formula, and the total weight of the infant formula is 1000 kg, and the infant formula comprises the following raw materials:
1000 kg of raw milk, 674.1 kg of the protein composition of example 4, 35 kg of sunflower oil, 50 kg of soybean oil, 100 kg of OPO structural fat, 13 kg of fructo-oligosaccharide powder, 25 kg of galacto-oligosaccharide syrup, 18.85 kg of compound nutrient, 12 kg of DHA, 22 kg of ARA and 0.1 kg of bifidobacterium;
wherein the compound nutrients comprise about 3.5 kg of compound vitamin nutrition package, about 1.5 kg of choline chloride nutrition package, about 10 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, about 0.85 kg of magnesium chloride nutrition package and about 2 kg of potassium chloride nutrition package, and the base material of each nutrition package is lactose.
The preparation process of the infant formula of the embodiment is as in the embodiment 13.
Wherein, the whey protein content of the protein composition in the infant formula obtained in the example is 60%, the casein content is 40%, and the total protein content is 100%;
the infant formula obtained in this example had a total protein content of 16.53g/100g, an alpha-lactalbumin content of 4.236g/100g and a beta-casein content of 5.161g/100g.
Example 15
The embodiment provides infant formula, which contains a protein composition capable of improving the protein digestion performance in the infant formula, and the total weight of the infant formula is 1000 kg, and the infant formula comprises the following raw materials:
850 kg of raw milk, 675.8 kg of the protein composition of example 3, 20 kg of corn oil, 40 kg of soybean oil, 85 kg of OPO structural fat, 17 kg of fructooligosaccharide powder, 40 kg of galactooligosaccharide syrup, 13 kg of compound nutrients, 8.6 kg of DHA, 15 kg of ARA and 0.1 kg of bifidobacterium;
wherein the compound nutrients comprise about 3.5 kg of compound vitamin nutrition package, about 0.75 kg of choline chloride nutrition package, about 5 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, about 0.75 kg of magnesium chloride nutrition package and about 2 kg of potassium chloride nutrition package, and the base material of each nutrition package is lactose.
The preparation process of the infant formula of the embodiment is as in the embodiment 13.
Wherein, the whey protein content of the protein composition in the infant formula obtained in the example is 60%, the casein content is 40%, and the total protein content is 100%;
the infant formula obtained in this example had a total protein content of 15.92g/100g, an alpha-lactalbumin content of 3.43g/100g and a beta-casein content of 4.61g/100g.
Example 16
The embodiment provides infant formula, which contains a protein composition capable of improving the protein digestion performance in the infant formula, and the total weight of the infant formula is 1000 kg, and the infant formula comprises the following raw materials:
1000 kg of raw milk, 671 kg of the protein composition of example 7, 50 kg of corn oil, 65 kg of soybean oil, 35 kg of sunflower oil, 6 kg of fructooligosaccharide powder, 50 kg of galactooligosaccharide syrup, 17 kg of compound nutrient, 10 kg of DHA, 12 kg of ARA and 0.1 kg of bifidobacterium;
wherein the compound nutrients comprise about 3.5 kg of compound vitamin nutrition package, about 0.75 kg of choline chloride nutrition package, about 9 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, about 0.75 kg of magnesium chloride nutrition package and about 2 kg of potassium chloride nutrition package, and the base material of each nutrition package is lactose.
The preparation process of the infant formula of the embodiment is as in the embodiment 13.
Wherein, the whey protein content of the protein composition in the infant formula obtained in the example is 35%, the casein content is 65%, and the total protein content is 100%;
the infant formula obtained in this example had a total protein content of 14.58g/100g, an alpha-lactalbumin content of 1.829g/100g and a beta-casein content of 2.521g/100g.
Example 17
The embodiment provides infant formula, which contains a protein composition capable of improving the protein digestion performance in the infant formula, and the total weight of the infant formula is 1000 kg, and the infant formula comprises the following raw materials:
1000 kg of raw milk, 675 kg of the protein composition of example 9, 40 kg of corn oil, 68 kg of soybean oil, 55 kg of sunflower oil, 12 kg of fructooligosaccharide powder, 20 kg of galactooligosaccharide syrup, 13 kg of compound nutrient, 10 kg of DHA, 12 kg of ARA and 0.1 kg of bifidobacterium;
wherein the compound nutrients comprise about 3.5 kg of compound vitamin nutrition package, about 0.75 kg of choline chloride nutrition package, about 5 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, about 0.75 kg of magnesium chloride nutrition package and about 2 kg of potassium chloride nutrition package, and the base material of each nutrition package is lactose.
The preparation process of the infant formula of the embodiment is as in the embodiment 13.
Wherein, the whey protein content of the protein composition in the infant formula obtained in the example is 50%, the casein content is 50%, based on the total protein content is 100%;
the infant formula obtained in this example had a total protein content of 14.16g/100g, an alpha-lactalbumin content of 3.118g/100g and a beta-casein content of 3.027g/100g.
Example 18
The embodiment provides infant formula, which contains a protein composition capable of improving the protein digestion performance in the infant formula, and the total weight of the infant formula is 1000 kg, and the infant formula comprises the following raw materials:
3000 kg of raw milk, 675.9 kg of the protein composition of example 10, 80 kg of OPO structural fat, 25 kg of fructo-oligosaccharide powder, 30 kg of galacto-oligosaccharide syrup, 13 kg of compound nutrient, 8 kg of DHA, 2 kg of phospholipid, 10 kg of ARA and 0.1 kg of bifidobacterium;
wherein the compound nutrients comprise about 2.5 kg of compound vitamin nutrition package, about 1.1 kg of choline chloride nutrition package, about 8 kg of calcium powder nutrition package, about 1 kg of mineral nutrition package, and lactose as the base material of each nutrition package.
The preparation process of the infant formula of the embodiment is as in the embodiment 13.
Wherein, the whey protein content of the protein composition in the infant formula obtained in the example is 50%, the casein content is 50%, based on the total protein content is 100%;
the infant formula obtained in this example had a total protein content of 21.52g/100g, an alpha-lactalbumin content of 3.465g/100g and a beta-casein content of 3.527g/100g.
Claims (23)
1. An infant formula comprising a protein composition capable of improving the digestibility of proteins in infant formula;
wherein, based on 100 percent of the total protein content of the infant formula, the protein composition contains 13.0 to 50.5 percent of alpha-lactalbumin and 15.0 to 35.0 percent of beta-casein.
2. The infant formula of claim 1 wherein the protein composition comprises from 15.0% to 50.5% of alpha-lactalbumin, based on 100% total protein content of the infant formula;
preferably, the protein composition contains 18.0% to 35.0% beta-casein, more preferably 22.0% to 32.0%, even more preferably 25.0% to 32.0%.
3. The infant formula of claim 1 wherein the protein composition comprises 20.0% -35.0% of alpha-lactalbumin and 26.0% -32.0% of beta-casein, based on 100% total protein content of the infant formula;
preferably, the protein composition contains 21.0% to 32.0% of alpha-lactalbumin and 29.0% to 32.0% of beta-casein, based on 100% total protein content of the infant formula;
more preferably, the protein composition contains 32.0% of alpha-lactalbumin and 32.0% of beta-casein, or the protein composition contains 29.0% of alpha-lactalbumin and 32.0% of beta-casein, or the protein composition contains 21.5% of alpha-lactalbumin and 29.0% of beta-casein, or the protein composition contains 21.0% of alpha-lactalbumin and 26.0% of beta-casein, based on 100% total protein content of the infant formula.
4. The infant formula according to claim 1 or 2, wherein the content of whey protein in the protein composition is 33.0% or more based on 100% of the total protein content of the infant formula;
preferably, the whey protein is present in the protein composition in an amount of 35.0% to 90.0%;
more preferably, the whey protein is present in the protein composition in an amount of 40.0% to 80.0%;
further preferably, the whey protein is present in the protein composition in an amount of 50.0% to 75.0%;
further preferably, the whey protein is present in the protein composition in an amount of 60.0% to 70.0%.
5. The infant formula according to any one of claims 1 to 4, wherein the casein content of the protein composition is 15.0% or more based on 100% total protein content of the infant formula;
preferably, the casein content of the protein composition is 15.0% -65.0%;
more preferably, the casein content of the protein composition is 28.0% -60.0%;
further preferably, the casein content of the protein composition is 32.0% -55.0%;
further preferably, the casein content of the protein composition is 38.0% -40.0%.
6. The infant formula according to any one of claims 1 to 5, wherein the protein composition is added in an amount of 540 to 690 parts by weight based on 1000 parts by weight of the infant formula.
7. The infant formula of any one of claims 1-6 wherein the infant formula has a total protein content of 10-23g/100g.
8. Infant formula according to any one of claims 1-7, wherein the infant formula has an alpha-lactalbumin content of 1.50-5.30g/100g and a beta-casein content of 2.00-5.20g/100g.
9. The infant formula of any one of claims 1-8, wherein the protein composition is prepared from one or more raw materials comprising liquid milk, milk powder, whey protein powder, casein powder;
preferably, the milk powder comprises whole milk powder and/or skimmed milk powder;
preferably, the liquid milk comprises whole milk and/or skim milk;
preferably, the feedstock further comprises lactose.
10. The infant formula of any one of claims 1-9 wherein the infant formula has a total protein content of 10-23g/100g;
whey protein accounts for 38-70% of total protein;
The fat content is 15-29g/100g;
the linoleic acid content is 1800-5000mg/100g;
the alpha-linolenic acid content is 200-500mg/100g;
the content of dietary fiber is 0.95-6.3g/100g, preferably, the dietary fiber comprises galacto-oligosaccharide and fructo-oligosaccharide;
the carbohydrate content is 50-58g/100g.
11. The infant formula of any one of claims 1-10, wherein the source of protein of the infant formula comprises one or a combination of two or more of milk, whole milk powder, skim milk powder, whey protein powder, desalted whey powder, and the protein composition;
preferably, the infant formula milk powder comprises the following raw materials in parts by weight: 800-3500 parts of milk and 0-400 parts of skim milk powder; more preferably, part or all of the milk, skim milk powder is replaced with a whole milk powder and/or skim milk of comparable protein content;
preferably, the protein composition is composed of at least one of the following protein powders and/or milk powders: whey protein powder with the content of alpha-whey protein of 25% -95%, whey protein powder with the content of beta-casein of 35% -80%, whey protein powder with the content of protein of 60% -95%, and milk powder (preferably skimmed milk powder) with the content of protein of 15% -50%;
More preferably, the protein composition is composed of at least one of the following protein powders and/or milk powders:
(1) Whey protein powder with the alpha-whey protein content of 25% -55%;
(2) Whey protein powder with 75% -95% of alpha-whey protein content;
(3) Whey protein powder with the content of beta-casein of 35-70%;
(4) Whey protein powder with the content of beta-casein of 40% -80%;
(5) Whey protein powder with the protein content of 60% -95%;
(6) Milk powder (preferably skimmed milk powder) with protein content of 15% -50%.
12. The infant formula of claim 11, wherein the raw materials comprise, based on 1000 parts by weight of the infant formula: 0-170 parts of whey protein powder, 25-400 parts of desalted whey powder, 0-55 parts of alpha-whey protein powder and 0-45 parts of beta-casein powder.
13. Infant formula according to any of claims 1-12, wherein the source of fat of the infant formula comprises milk fat and/or anhydrous cream; preferably, vegetable oils and/or OPO structured fats are also included.
14. The infant formula of claim 13, wherein the vegetable oil comprises one or more of sunflower oil, corn oil, soybean oil, canola oil, coconut oil, palm oil, walnut oil, preferably one or more of sunflower oil, corn oil, and soybean oil.
15. The infant formula of claim 14, wherein the raw materials comprise, based on 1000 parts by weight of the infant formula: 0-80 parts of sunflower seed oil, 0-40 parts of corn oil, 0-80 parts of soybean oil, 0-140 parts of OPO structural fat and 0-4 parts of anhydrous cream.
16. The infant formula of claim 14 or 15 wherein:
the contents of linoleic acid and alpha-linolenic acid in the sunflower seed oil are respectively 7.6-8.9 percent and 0.25-0.38 percent;
the content of linoleic acid and alpha-linolenic acid in the corn oil is 53.0-56.20 percent and 0.9-1.6 percent respectively;
the contents of linoleic acid and alpha-linolenic acid in the soybean oil are respectively 50.0-53.5% and 7.6-9.6%;
the contents of linoleic acid and alpha-linolenic acid in the OPO structural fat are respectively 5.9-6.3 percent and 0.4-0.62 percent;
the contents of linoleic acid and alpha-linolenic acid in the canola oil are 16-19% and 8.0-10.6% respectively;
the contents of linoleic acid and alpha-linolenic acid in the coconut oil are respectively 1-3% and 0-1%;
the effective content of the 1, 3-dioleoyl-2-palmitic acid triglyceride in the OPO structural fat raw material is 40-70%.
17. The infant formula of any one of claims 1-16 wherein the raw materials of the infant formula further comprise lactose;
Preferably, the infant formula milk powder comprises the following raw materials in parts by weight: 125-550 parts by weight of lactose.
18. The infant formula of any one of claims 1-17 wherein the infant formula further comprises one or a combination of two or more of DHA, ARA, nucleotides, lactoferrin;
preferably, the infant formula milk powder comprises the following raw materials in parts by weight: 2-15 parts of DHA, 3-22 parts of ARA, 0-1.4 parts of lactoferrin and 0-0.7 part of nucleotide.
19. The infant formula of any one of claims 1-18 wherein the raw materials of the infant formula further comprise a compound nutrient comprising calcium powder, vitamins and minerals;
preferably, the infant formula milk powder comprises the following raw materials in parts by weight: 7-22 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals;
more preferably, the compound nutrients are added at least in the form of compound vitamin packs, calcium powder, mineral nutrient packs; further preferably, the compound nutrient is added in the form of at least the following nutritional packages:
1) The compound vitamin nutrition package comprises the following components in each gram of compound vitamin nutrition package:
Taurine: 140-340mg
Vitamin a: 1700-5800. Mu.gRE
Vitamin D:25-70 mug
Vitamin B1:3000-6800 mug
Vitamin B2:3500-6900 mug
Vitamin B6:2400-4000 μg
Vitamin B12:8-20 mug
Vitamin K1:200-700 mug
Vitamin C:155-700mg
Vitamin E:10-70mg alpha-TE
Nicotinamide: 10000-41550 mug
Folic acid: 500-920 μg
Biotin: 100-245 mug
Pantothenic acid: 7100-25230 μg
Inositol: 0-250mg
L-carnitine: 0-60mg
2) The mineral substance two-nutrition package comprises the following components in each gram of the mineral substance two-nutrition package:
calcium: 300-455mg
Phosphorus: 75-150mg
3) The mineral substance-nutrition package comprises the following components in each gram of the mineral substance-nutrition package:
iron: 40-110mg
Zinc: 23-90mg
Copper: 2600-4180 μg
Iodine: 500-995 μg
Selenium: 0-200 mu g
Manganese: 0-579 mug
4) The compound magnesium chloride nutrition package comprises the following components in per gram:
magnesium: 80-170mg
5) The compound potassium chloride nutrition package comprises the following components in per gram:
potassium: 400-580mg;
6) The choline chloride nutrition packet comprises the following components in per gram:
choline: 300-950mg;
preferably, based on 1000 parts by weight of infant formula milk powder, the addition amount of the compound vitamin nutrition package is 2-4 parts by weight, the addition amount of the mineral two nutrition packages is 2-12 parts by weight, the addition amount of the mineral one nutrition package is 0.5-3 parts by weight, the addition amount of the compound magnesium chloride nutrition package is 0-2 parts by weight, the addition amount of the compound potassium chloride nutrition package is 0-4.5 parts by weight, the addition amount of the choline chloride nutrition is 0-2 parts by weight, and the base material of each nutrition package is preferably lactose or L-sodium ascorbate.
20. The infant formula of any one of claims 1-19 wherein the raw materials of the infant formula further comprise probiotics;
preferably, the probiotic is bifidobacteria;
more preferably, the infant formula comprises the following raw materials in parts by weight: 0.1 to 0.2 parts by weight, more preferably 0.18 to 0.2 parts by weight of bifidobacterium;
further preferably, the content of bifidobacteria per part by weight of the bifidobacteria powder is 3X 10 10 CFU or more.
21. The infant formula of any one of claims 1-20 wherein the infant formula comprises, based on 1000 parts by weight of infant formula, raw materials including:
22. the infant formula of any one of claims 1-21 wherein the infant formula is suitable for infants and children between 0-7 years old.
23. A method of preparing the infant formula of any one of claims 1-22, comprising the steps of:
mixing the milk, powder raw materials and melted grease raw materials subjected to rough filtration, homogenization and sterilization, and adding compound nutrients to obtain mixed feed liquid;
filtering, homogenizing, cooling, concentrating, sterilizing, spray drying, fluidized bed drying, cooling to obtain dried milk powder, mixing with DHA, ARA, lactoferrin, nucleotide and bifidobacterium, and sieving to obtain infant formula milk powder;
Preferably, the primary pressure of the homogenization treatment of the mixed liquor is 105+/-5 bar, and the secondary pressure is 32+/-3 bar;
preferably, the concentration sterilization adopts double-effect concentration, more preferably, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; further preferably, the discharge concentrations are all 48% -52% dry matter;
preferably, the inlet air temperature of the spray drying is: 165-180 ℃, the exhaust temperature is 75-90 ℃, the pressure of the high-pressure pump is 160-210bar, and the negative pressure of the tower is-4 mbar to-2 mbar;
preferably, the fluidized bed drying and cooling comprises two times of drying and cooling, and the temperature of the milk powder after the two times of drying and cooling is 25-30 ℃; and mixing phospholipid with carrier, heating to 60-65deg.C, and dispersing on the surface of milk powder under the action of compressed air.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211474362.5A CN116250570A (en) | 2022-11-23 | 2022-11-23 | Infant formula milk powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211474362.5A CN116250570A (en) | 2022-11-23 | 2022-11-23 | Infant formula milk powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116250570A true CN116250570A (en) | 2023-06-13 |
Family
ID=86679933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211474362.5A Pending CN116250570A (en) | 2022-11-23 | 2022-11-23 | Infant formula milk powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116250570A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766225A (en) * | 2008-12-26 | 2010-07-07 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing alpha-whey protein powder and beta-casein and preparation method thereof |
| CN106259953A (en) * | 2015-06-01 | 2017-01-04 | 内蒙古伊利实业集团股份有限公司 | Breast milk 0-12 month babies ' formula milk powder containing nucleotide and preparation method thereof |
| CN109662150A (en) * | 2018-12-26 | 2019-04-23 | 光明乳业股份有限公司 | A kind of breast milk protein compositions and the babies ' formula milk powder containing it |
| CN111990462A (en) * | 2020-08-18 | 2020-11-27 | 黑龙江省完达山乳业股份有限公司 | Infant formula containing protein composition and preparation method thereof |
| CN113841740A (en) * | 2021-09-06 | 2021-12-28 | 内蒙古伊利实业集团股份有限公司 | Sialic acid-containing infant formula milk powder and preparation method thereof |
| WO2022068137A1 (en) * | 2020-09-29 | 2022-04-07 | 内蒙古伊利实业集团股份有限公司 | Whey protein composition, and preparation method therefor and use thereof |
| US20220132901A1 (en) * | 2019-03-29 | 2022-05-05 | Frieslandcampina Nederland B.V. | Nutritional compositions showing phase separation under gastric conditions and methods for preparing the same |
-
2022
- 2022-11-23 CN CN202211474362.5A patent/CN116250570A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766225A (en) * | 2008-12-26 | 2010-07-07 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing alpha-whey protein powder and beta-casein and preparation method thereof |
| CN106259953A (en) * | 2015-06-01 | 2017-01-04 | 内蒙古伊利实业集团股份有限公司 | Breast milk 0-12 month babies ' formula milk powder containing nucleotide and preparation method thereof |
| CN109662150A (en) * | 2018-12-26 | 2019-04-23 | 光明乳业股份有限公司 | A kind of breast milk protein compositions and the babies ' formula milk powder containing it |
| US20220132901A1 (en) * | 2019-03-29 | 2022-05-05 | Frieslandcampina Nederland B.V. | Nutritional compositions showing phase separation under gastric conditions and methods for preparing the same |
| CN111990462A (en) * | 2020-08-18 | 2020-11-27 | 黑龙江省完达山乳业股份有限公司 | Infant formula containing protein composition and preparation method thereof |
| WO2022068137A1 (en) * | 2020-09-29 | 2022-04-07 | 内蒙古伊利实业集团股份有限公司 | Whey protein composition, and preparation method therefor and use thereof |
| CN113841740A (en) * | 2021-09-06 | 2021-12-28 | 内蒙古伊利实业集团股份有限公司 | Sialic acid-containing infant formula milk powder and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107259527B (en) | Nutritional composition | |
| Mehra et al. | Nutritional attributes of bovine colostrum components in human health and disease: A comprehensive review | |
| CN112931628B (en) | Liposome simulating breast milk lipid structure, formula powder for premature infant and preparation method | |
| AU2021340764B2 (en) | Infant formula milk powder rich in milk fat globule membrane protein, phospholipid and oligosaccharide, and preparation method therefor | |
| EP2039365B1 (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
| CN111990462A (en) | Infant formula containing protein composition and preparation method thereof | |
| JP2010059155A (en) | Agent for improving exercise function | |
| KR100509681B1 (en) | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey | |
| CN111345358A (en) | Child formula goat milk powder rich in lactophospholipid and preparation method thereof | |
| CN108741100B (en) | Preparation method and application of chelated iron donkey-hide gelatin glycopeptide | |
| CN114208893B (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN114128767B (en) | Milk protein partially hydrolyzed hypoallergenic infant formulas containing breast milk oligosaccharides | |
| CN114145353A (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN116250570A (en) | Infant formula milk powder and preparation method thereof | |
| CN113841740A (en) | Sialic acid-containing infant formula milk powder and preparation method thereof | |
| CN107529805A (en) | Composition comprising choline and its derivative, preparation method and use | |
| KR20160075524A (en) | Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation | |
| CN111937966A (en) | Formula milk powder capable of reducing blood fat and preparation method thereof | |
| CN115316488A (en) | Method for improving digestibility of micellar casein | |
| JPH06165655A (en) | Composition for reducing cholesterol | |
| Goldman et al. | Future research in human milk | |
| WO2023142838A1 (en) | Method for improving digestion performance for protein in food, and protein composition and food containing same | |
| CN113455551A (en) | Phospholipid-rich milk fat globule membrane, preparation method thereof and application thereof in promoting brain development and relieving cognitive function decline | |
| CN114145356B (en) | Formula milk powder capable of improving immune response and preparation method and application thereof | |
| CN117481203A (en) | Formula milk powder for children and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |